News
BTG Reports Positive Results from Second Phase III Varicose Veins Study
www.genengnews.com
[Genetic Engineering News] outcome of our two pivotal trails, Vanish-1 and Vanish-2, which met all their endpoints with a high degree of statistical significance, we are on track to submit our US regulatory application by the end of 2012,” remarks Louise Makin, BTG CEO.
BTG lifts full year revenue outlook – Quick facts
www.rttnews.com
[RTT News] - Louise Makin, BTG's CEO, said, "We have delivered a strong financial and operating performance across the business. Our development programmes are on track and we have made good progress in our Interventional Medicine business.
BTG boosted by drug royalties
www.whatinvestment.co.uk
[What Investment] - Louise Makin, CEO of BTG, commented, 'We have delivered a strong financial and operating performance across the business. 'Our development programmes are on track and we have made good progress in our interventional medicine business.
Google News: BTG gains US approval for kidney drug
[ShareCast] - Louise Makin, Chief Executive of BTG, commented: "Voraxaze is the first product BTG has taken through to approval in the US and we look forward to its launch over coming months.” The Chief Medical Officer, Guenter R. Janhofer, added “In the clinical
sorted by relevance / date